Lexaria Bioscience (LEXX) Retained Earnings (2011 - 2026)
Lexaria Bioscience (LEXX) posted Retained Earnings of $73.3 million for Q2 2026, up 210.15% sequentially from -$66.5 million in Q1 2026, and up 10.36% YoY from $66.4 million in Q2 2025.
Lexaria Bioscience (LEXX) Retained Earnings (2011 - 2026) Analysis & Trends
Lexaria Bioscience has reported Retained Earnings for 16 years, with the latest figure at $73.3 million in Q2 2026.
- Quarterly Retained Earnings rose 10.36% year-over-year to $73.3 million in Q2 2026, while the trailing twelve-month figure through May 2026 was $73.3 million (up 10.36% YoY) and the FY2025 annual result came in at $66.5 million, up 228.98% from the prior year.
- Retained Earnings climbed to $73.3 million in Q2 2026 per LEXX's latest filing, from -$66.5 million in the prior quarter.
- Over five years, Retained Earnings peaked at $73.3 million in Q2 2026 and troughed at -$66.5 million in Q1 2026.
- A 5-year average of -$10.3 million and a median of -$36.4 million in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings soared 247.79% in 2022, then tumbled 282861.25% in 2025.
- Over 5 years, Retained Earnings stood at $47.1 million in 2022, then tumbled by 99.99% to $4372.0 in 2023, then sank by 625.87% to -$22991.0 in 2024, then sank by 282861.25% to -$65.1 million in 2025, then soared by 212.61% to $73.3 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $73.3 million, -$66.5 million, and -$65.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.20 Bn | 131.35 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.09 Bn | 78.10 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 59.04 Bn | 53.90 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.04 Bn | 36.94 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.04 Bn | 9.65 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.34 Bn | 26.50 Bn | - | 4.38 Bn |
| 10 | Lexaria Bioscience | 10.14 Mn | 6.52 Mn | - | 73.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 73.26 Mn |
| Feb 28, 2026 | -66.51 Mn |
| Nov 30, 2025 | -65.06 Mn |
| Aug 31, 2025 | 66.50 Mn |
| May 31, 2025 | 66.38 Mn |
| Feb 28, 2025 | -118,246.00 |
| Nov 30, 2024 | -22,991.00 |
| Aug 31, 2024 | -51.56 Mn |
| May 31, 2024 | -49.37 Mn |
| Feb 29, 2024 | -47.59 Mn |
| Nov 30, 2023 | 4,372.00 |
| Aug 31, 2023 | -45.76 Mn |
| May 31, 2023 | -44.52 Mn |
| Feb 28, 2023 | -42.15 Mn |
| Nov 30, 2022 | 47.11 Mn |
| Aug 31, 2022 | 47.04 Mn |
| May 31, 2022 | -37.63 Mn |
| Feb 28, 2022 | -35.25 Mn |
| Nov 30, 2021 | -33.82 Mn |
| Aug 31, 2021 | -31.83 Mn |